Selecting Informative Patients for Phase 2 Progressive Trials in MS: Design Considerations for Phase 2 Clinical...

Area of Science:

• Neuroimmunology
• Clinical Trial Design
• Progressive Multiple Sclerosis Therapeutics

Background:

• Relapsing-remitting multiple sclerosis (MS) has numerous treatments, but progressive MS forms lack effective therapeutic options.
• Phase 2 clinical trials are essential for advancing novel treatments for progressive MS.
• Optimizing phase 2 trial efficiency is critical due to the complexity and slow progression of MS.

Purpose of the Study:

• To review and discuss strategies for enhancing the efficiency of phase 2 clinical trials in progressive multiple sclerosis.
• To identify methods for accelerating the identification of successful treatments for progressive MS.
• To provide guidance on designing informative and participant-minimal phase 2 trials.

Main Methods:

• The review discusses key aspects of phase 2 clinical trial design.
• Strategies examined include cohort selection, outcome selection, cohort enrichment, and dosing selection.
• Focus is on optimizing efficiency for progressive MS trials.

Main Results:

• Optimizing cohort selection can improve trial relevance and reduce variability.
• Careful outcome selection ensures sensitive detection of treatment effects.
• Cohort enrichment and strategic dosing can enhance statistical power and reduce sample size.

Conclusions:

• Efficient phase 2 trial design is paramount for advancing progressive MS therapeutics.
• Implementing strategies such as optimized cohort selection, outcome measures, enrichment, and dosing can accelerate treatment discovery.
• Improved trial efficiency will facilitate the development of much-needed therapies for progressive MS patients.